Logo image of BAI.AS

BENEVOLENTAI (BAI.AS) Stock Fundamental Analysis

AMS:BAI - Euronext Amsterdam - LU2355630455 - Common Stock - Currency: EUR

0.1095  +0 (+0.92%)

Fundamental Rating

2

Taking everything into account, BAI scores 2 out of 10 in our fundamental rating. BAI was compared to 52 industry peers in the Pharmaceuticals industry. The financial health of BAI is average, but there are quite some concerns on its profitability. BAI is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

BAI had negative earnings in the past year.
BAI had a negative operating cash flow in the past year.
BAI.AS Yearly Net Income VS EBIT VS OCF VS FCFBAI.AS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 -50M -100M -150M

1.2 Ratios

Looking at the Return On Assets, with a value of -54.61%, BAI is doing worse than 80.77% of the companies in the same industry.
With a Return On Equity value of -73.07%, BAI is not doing good in the industry: 76.92% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -54.61%
ROE -73.07%
ROIC N/A
ROA(3y)-60.56%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BAI.AS Yearly ROA, ROE, ROICBAI.AS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 0 500 1K 1.5K

1.3 Margins

BAI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BAI.AS Yearly Profit, Operating, Gross MarginsBAI.AS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 -500 -1K -1.5K -2K -2.5K

More info and screens

5

2. Health

2.1 Basic Checks

BAI does not have a ROIC to compare to the WACC, probably because it is not profitable.
BAI has more shares outstanding than it did 1 year ago.
The debt/assets ratio for BAI has been reduced compared to a year ago.
BAI.AS Yearly Shares OutstandingBAI.AS Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 50M 100M
BAI.AS Yearly Total Debt VS Total AssetsBAI.AS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -6.96, we must say that BAI is in the distress zone and has some risk of bankruptcy.
BAI has a worse Altman-Z score (-6.96) than 73.08% of its industry peers.
A Debt/Equity ratio of 0.05 indicates that BAI is not too dependend on debt financing.
The Debt to Equity ratio of BAI (0.05) is better than 82.69% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z -6.96
ROIC/WACCN/A
WACC7.64%
BAI.AS Yearly LT Debt VS Equity VS FCFBAI.AS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 100M 200M

2.3 Liquidity

BAI has a Current Ratio of 3.30. This indicates that BAI is financially healthy and has no problem in meeting its short term obligations.
BAI has a Current ratio of 3.30. This is amongst the best in the industry. BAI outperforms 88.46% of its industry peers.
A Quick Ratio of 3.30 indicates that BAI has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 3.30, BAI belongs to the best of the industry, outperforming 90.38% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.3
Quick Ratio 3.3
BAI.AS Yearly Current Assets VS Current LiabilitesBAI.AS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 33.78% over the past year.
Looking at the last year, BAI shows a very negative growth in Revenue. The Revenue has decreased by -55.80% in the last year.
EPS 1Y (TTM)33.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.91%
Revenue 1Y (TTM)-55.8%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-46.5%

3.2 Future

Based on estimates for the next years, BAI will show a very strong growth in Earnings Per Share. The EPS will grow by 23.43% on average per year.
The Revenue is expected to grow by 21.14% on average over the next years. This is a very strong growth
EPS Next Y8.46%
EPS Next 2Y14.81%
EPS Next 3Y23.43%
EPS Next 5YN/A
Revenue Next Year-31.89%
Revenue Next 2Y-7.92%
Revenue Next 3Y19.4%
Revenue Next 5Y21.14%

3.3 Evolution

BAI.AS Yearly Revenue VS EstimatesBAI.AS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M
BAI.AS Yearly EPS VS EstimatesBAI.AS Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -0.2 -0.4 -0.6 -0.8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BAI. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BAI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BAI.AS Price Earnings VS Forward Price EarningsBAI.AS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BAI.AS Per share dataBAI.AS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4

4.3 Compensation for Growth

BAI's earnings are expected to grow with 23.43% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.81%
EPS Next 3Y23.43%

More info and screens

0

5. Dividend

5.1 Amount

BAI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BENEVOLENTAI

AMS:BAI (3/7/2025, 7:00:00 PM)

0.1095

+0 (+0.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A N/A
Earnings (Next)03-13 2025-03-13/amc
Inst Owners22.95%
Inst Owner ChangeN/A
Ins Owners23.71%
Ins Owner ChangeN/A
Market Cap15.66M
Analysts80
Price Target2.75 (2411.42%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)50%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.71
P/FCF N/A
P/OCF N/A
P/B 0.19
P/tB 0.28
EV/EBITDA N/A
EPS(TTM)-0.51
EYN/A
EPS(NY)-0.28
Fwd EYN/A
FCF(TTM)-0.4
FCFYN/A
OCF(TTM)-0.39
OCFYN/A
SpS0.04
BVpS0.59
TBVpS0.39
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -54.61%
ROE -73.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-60.56%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 38.04%
Cap/Sales 18.94%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.3
Quick Ratio 3.3
Altman-Z -6.96
F-Score1
WACC7.64%
ROIC/WACCN/A
Cap/Depr(3y)35.9%
Cap/Depr(5y)N/A
Cap/Sales(3y)15.35%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)33.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.91%
EPS Next Y8.46%
EPS Next 2Y14.81%
EPS Next 3Y23.43%
EPS Next 5YN/A
Revenue 1Y (TTM)-55.8%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-46.5%
Revenue Next Year-31.89%
Revenue Next 2Y-7.92%
Revenue Next 3Y19.4%
Revenue Next 5Y21.14%
EBIT growth 1Y38.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year16.65%
EBIT Next 3Y20.43%
EBIT Next 5YN/A
FCF growth 1Y25.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y25.73%
OCF growth 3YN/A
OCF growth 5YN/A